Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Anavex Life Sciences Corp. has announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer's disease. This study will evaluate the safety, tolerability, pharmacokinetics, and possible clinical benefits of ANAVEX PLUS in Alzheimer's disease patients and other diseases associated with dementia and cognitive impairment.
ANAVEX PLUS is a proprietary drug combination of ANAVEX 2-73 with donepezil (Aricept®) as a potential novel combination drug for Alzheimer's disease. Aricept® (donepezil) is now generic. ANAVEX 2-73 showed in combination with Aricept® (donepezil) results for memory improvement by up to 80% in animal models. A patent application was filed in the US for the combination of ANAVEX PLUS and, if granted, would extend at least until 2033. In a humanized calibrated cortical network computer model ANAVEX PLUS showed an ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks. These data represent more than twice the ADAS-Cog response exhibited by donepezil (Aricept®) alone.
"The support by The Roskamp Instititute shows the confidence in this new therapeutic approach for Alzheimer's disease to develop innovative treatments for the many unmet needs of patients with this disorder," said Christopher U. Missling, PhD, Anavex's President and Chief Executive Officer. "It also underscores Anavex's deep commitment in the development of novel therapeutics for diseases of the central nervous system."
Fiona Crawford, PhD, President of The Roskamp Institute, said "ANAVEX PLUS has shown promising pre-clinical data and represents a novel approach for the treatment of Alzheimer's disease and we are excited to work with the Anavex team."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Alzheimer's / Dementia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Anavex Life Sciences Corp. "Anavex agreement with The Roskamp Institute to advance the clinical development of ANAVEX PLUS." Medical News Today. MediLexicon, Intl., 15 Jan. 2014. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/271210>
Anavex Life Sciences Corp. (2014, January 15). "Anavex agreement with The Roskamp Institute to advance the clinical development of ANAVEX PLUS." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271210.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.